Mirum Pharmaceuticals, Inc.
MIRM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $337 | $186 | $77 | $19 |
| % Growth | 80.8% | 141.8% | 302.7% | – |
| Cost of Goods Sold | $82 | $47 | $12 | $2 |
| Gross Profit | $255 | $139 | $65 | $17 |
| % Margin | 75.8% | 74.8% | 83.9% | 90.1% |
| R&D Expenses | $141 | $103 | $107 | $131 |
| G&A Expenses | $191 | $140 | $0 | $50 |
| SG&A Expenses | $202 | $146 | $89 | $59 |
| Sales & Mktg Exp. | $12 | $6 | $0 | $9 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $343 | $248 | $196 | $191 |
| Operating Income | -$88 | -$109 | -$131 | -$173 |
| % Margin | -26% | -58.6% | -170.3% | -906.1% |
| Other Income/Exp. Net | $1 | -$53 | -$11 | $89 |
| Pre-Tax Income | -$87 | -$162 | -$142 | -$84 |
| Tax Expense | $1 | $1 | -$6 | $0 |
| Net Income | -$88 | -$163 | -$136 | -$84 |
| % Margin | -26.1% | -87.7% | -176% | -438.9% |
| EPS | -1.85 | -4 | -4.01 | -2.77 |
| % Growth | 53.8% | 0.2% | -44.8% | – |
| EPS Diluted | -1.85 | -4 | -4.02 | -2.77 |
| Weighted Avg Shares Out | 48 | 41 | 34 | 30 |
| Weighted Avg Shares Out Dil | 48 | 41 | 34 | 30 |
| Supplemental Information | – | – | – | – |
| Interest Income | $14 | $14 | $4 | $0 |
| Interest Expense | $14 | $15 | $16 | $18 |
| Depreciation & Amortization | $24 | $11 | $3 | $1 |
| EBITDA | -$49 | -$136 | -$123 | -$65 |
| % Margin | -14.5% | -73.2% | -159.4% | -341.7% |